Fluorescent In Situ Hybridization Probe Market

Market Overview The global market for Fluorescent In Situ Hybridization (FISH) probes is projected to expand significantly, rising from USD 1.11 billion in 2025 to USD 1.67 billion by 2031, demonstrating a Compound Annual Growth Rate (CAGR) of 7.04%. FISH probes are specialized cytogenetic instruments employed to identify and pinpoint specific DNA sequences on chromosomes through the use of fluorescent genetic markers. This market's primary growth impetus stems from the increasing worldwide incidence of diseases like cancer and various genetic abnormalities, which demand precise molecular diagnostic tools to inform personalized treatment approaches. This growing disease burden directly stimulates the need for cytogenetic testing and advanced genomic analysis. For instance, the American Cancer Society anticipates approximately 2,041,910 new cancer diagnoses in the United States in 2025, underscoring the critical requirement for accurate diagnostic interventions. The market also benefits from the expanding adoption of FISH probes within clinical settings for the diagnosis and profiling of hematological malignancies and solid tumors. Conversely, a significant hurdle to market growth is the considerable operational expenses tied to fluorescence microscopy infrastructure and the intricate nature of the testing protocols. The necessity for highly trained personnel to interpret results, combined with the substantial capital outlay for imaging equipment, can restrict access in settings with limited resources, thereby hindering the widespread acceptance of FISH testing when compared to more affordable diagnostic alternatives. Market Driver The primary impetus for the global Fluorescent In Situ Hybridization Probe market is the rapid rise of personalized medicine and companion diagnostics. With clinicians increasingly favoring targeted therapies that necessitate specific biomarkers for patient selection, the demand for FISH probes—used to identify genetic anomalies such as HER2 amplification or ALK rearrangements—has seen a considerable increase. This trend solidifies the importance of cytogenetic analysis in oncology, where accurate molecular profiling is essential for effective treatment. For example, the 'Personalized Medicine at FDA: The Scope & Significance of Progress in 2024' report by the Personalized Medicine Coalition, published in May 2025, indicated that 18 new personalized medicines were FDA-approved in 2024, representing about 38% of all new therapeutic molecular entities. This highlights modern pharmacotherapy's reliance on strong diagnostic tools for precise patient stratification. Concurrent technological advancements in multiplexing and automated FISH systems are transforming laboratory operations by alleviating the constraints of manual analysis. Probe manufacturers are creating pre-optimized and automated panels that substantially reduce turnaround times and improve signal-to-noise ratios, thereby boosting diagnostic capacity in busy pathology labs. Empire Genomics, for instance, introduced the first pre-optimized hematology FISH probe panels for its CellWriter S automated platform in April 2025, aiming to streamline testing. These innovations are vital for sustained market growth, as demonstrated by the financial success of leading industry players; Revvity reported a $1.5 billion revenue for its Diagnostics segment in fiscal year 2024, reflecting consistent commercial demand for advanced diagnostic solutions. Market Challenge The global market for Fluorescent In Situ Hybridization (FISH) probes faces considerable limitations due to the elevated operational costs and the resource-intensive characteristics of its testing methodologies. Performing FISH analysis necessitates a substantial capital outlay for sophisticated fluorescence microscopy equipment and depends on intricate protocols that demand exceptional precision. This significant financial and technical load acts as a formidable barrier, largely restricting the adoption of FISH testing to adequately funded reference laboratories and major academic institutions. As a result, smaller community hospitals and healthcare facilities with limited resources frequently cannot justify the investment, which directly curtails the potential customer base and impedes the widespread commercial uptake of these diagnostic instruments. Adding to these difficulties, a severe scarcity of specialized laboratory professionals skilled in interpreting complex genomic data further exacerbates the challenge. This shortage of expert personnel creates operational bottlenecks, contributing to extended turnaround times and diminished testing capabilities. The American Society for Clinical Pathology reported a 28.5% vacancy rate in anatomic pathology departments in 2025, underscoring a critical lack of the specialized workforce essential for solid tumor profiling and advanced diagnostics. This gap compels numerous healthcare providers to opt for alternative, less labor-intensive diagnostic techniques, directly hindering the volume growth and revenue generation potential of the FISH probe market. Market Trends A significant market transformation is underway with the swift growth of RNA FISH in spatial transcriptomics and single-cell analysis, extending its utility beyond traditional DNA-focused applications to enable the visualization of gene expression within tissue structures. This trend is fueled by the escalating demand to comprehend the tumor microenvironment and cellular heterogeneity, where RNA-based probes facilitate mapping transcript distribution at a subcellular level. The commercial ramifications of this evolution are apparent in the rising consumption of spatial biology reagents, which are evolving into a steady revenue source for probe producers. For instance, 10x Genomics' 'Preliminary Select Fourth Quarter and Full Year 2024 Results' report from January 2025 indicated that the company generated approximately $121.1 million in spatial consumables revenue for fiscal year 2024, underscoring the substantial and continuous use of these advanced in situ hybridization platforms in life science research. Concurrently, the integration of FISH assays with Next-Generation Sequencing (NGS) platforms marks a crucial advancement in diagnostic methodologies, creating a holistic approach to genomic profiling. Although NGS provides high-throughput sequence analysis, FISH remains essential for confirming structural variations and identifying translocations that sequencing might overlook, prompting laboratories to increasingly adopt combined testing models. This complementary approach ensures reliable detection of clinically significant biomarkers, thereby sustaining the demand for cytogenetic testing services alongside molecular sequencing. NeoGenomics, as reported in its 'Fourth Quarter and Full Year 2024 Results' in February 2025, achieved $661 million in full-year 2024 revenue, a performance attributed to robust volume growth across its extensive oncology testing portfolio that incorporates both cytogenetic and advanced molecular techniques. Key Market Players * Thermo Fisher Scientific Inc. * PerkinElmer Health Sciences Inc * Biodot Inc * New Horizons Diagnostic Corp * Merck KGaA * Agilent Technologies, Inc. * Abnova Corp. * Genemed Biotechnologies Inc * F. Hoffmann-La Roche Ltd * Oxford Gene Technology Ltd Report Scope In this report, the Global Fluorescent In Situ Hybridization Probe Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below: # Fluorescent In Situ Hybridization Probe Market, By Technology * Q FISH * FLOW FISH * Others # Fluorescent In Situ Hybridization Probe Market, By Type * DNA * RNA # Fluorescent In Situ Hybridization Probe Market, By Application * Cancer Research * Genetic Diseases * Others # Fluorescent In Situ Hybridization Probe Market, By End-Use * Research * Clinical * Companion Diagnostics # Fluorescent In Situ Hybridization Probe Market, By Region * North America United States Canada Mexico * Europe France United Kingdom Italy Germany Spain * Asia Pacific China India Japan Australia South Korea * South America Brazil Argentina Colombia * Middle East & Africa South Africa Saudi Arabia UAE Competitive Landscape Company Profiles: Detailed analysis of the major companies present in the Global Fluorescent In Situ Hybridization Probe Market. Available Customizations: Global Fluorescent In Situ Hybridization Probe Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report: Company Information * Detailed analysis and profiling of additional market players (up to five).